Business Context and Reporting Period
Company: National Research Corporation (NRC Health)
Filing Type: Form 8-K (Current Report)
Report Date: April 28, 2025
Reporting Period: First Quarter ended March 31, 2025
This filing serves as a notification of the Company's Q1 2025 financial results and a significant corporate action regarding share repurchases. The detailed financial data is contained in the press release furnished as Exhibit 99.1.
Key Financial Metrics
The 8-K filing itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not explicitly stated in the text of this current report.
Material Changes and Corporate Actions
- Share Repurchase Authorization: On April 25, 2025, the Board of Directors approved a new authorization to repurchase up to 1,000,000 additional shares of the Company's common stock.
- Financial Results Announcement: The Company announced its operating and financial results for the quarter ended March 31, 2025, on April 28, 2025.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers. Management notes that statements regarding future results are based on current beliefs and expectations and are subject to significant risks and uncertainties. Actual results may differ materially from those anticipated. Specific guidance or outlook figures are not provided in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for specific Q1 2025 revenue, earnings per share, and cash flow figures.
- Verify the terms and timeline of the newly authorized 1 million share repurchase program.
- Check for any updated full-year guidance provided in the accompanying press release.
- Confirm the Company's current cash position and debt levels as reported in the Q1 results.